An ophthalmic pharmaceutical company has commenced two Phase 3 clinical studies to evaluate its eye drop candidate for presbyopia. Read more

An ophthalmic pharmaceutical company has commenced two Phase 3 clinical studies to evaluate its eye drop candidate for presbyopia. Read more
Swiss drug giant Roche is poised to pursue regulatory clearance for its new faricimab antibody for diabetic macular edema (DME) after it produced a similar effect to Eylea in twin clinical trials, but with half the dosing regimen in several patients. Read more
Australian-operated company Harvest Technology Group has announced a new agreement to commence proof-of-concept trials with the Belgian producer of industrial smart glasses. Read more
The Federal Government has reversed its decision to restrict a major optical dispensing traineeship wage subsidy to new employees only, reinstating the original criteria that included longer term staff. Read more
Novartis has announced positive findings from its the Phase 3 trial assessing the efficacy and safety of Beovu (brolucizumab) to treat diabetic macular edema (DME). Read more
Nova Eye Medical is seeking a modification to the existing minimally invasive glaucoma surgery (MIGS) Medicare item number that only came into effect in May, stating the current wording has the unintended consequence of excluding microcatheter technology. Read more
Safilo is celebrating the 65th anniversary of its proprietary eyewear label Carrera with a relaunch of its most iconic designs. Read more
Japanese contact lens manufacturer Menicon has signed a joint development agreement with a US firm producing the world’s first augmented reality contact lens that overlays images and text on wearers’ natural field of vision. Read more
The pandemic has drastically altered the healthcare landscape and practices may have formulated new advertising campaigns accordingly. KAREN CROUCH explains how to remain compliant. Read more
As the current economic climate prompts optometrists to reconsider practice valuations, exit plans and buyer interest, RHIANNON BOWMAN reflects on where opportunities lie for the next generation of independent practice owners. Read more